Skip to content
Brilinta, Brilique(ticagrelor)
Brilinta, Brilique (ticagrelor) is a small molecule pharmaceutical. Ticagrelor was first approved as Brilique on 2010-12-03. It has been approved in Europe to treat acute coronary syndrome and peripheral vascular diseases. The pharmaceutical is active against P2Y purinoceptor 12. In addition, it is known to target equilibrative nucleoside transporter 1.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Brilinta (generic drugs available since 2019-01-23)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ticagrelor
Tradename
Company
Number
Date
Products
BRILINTAAstraZenecaN-022433 RX2011-07-20
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
brilintaNew Drug Application2023-01-05
ticagrelorANDA2020-07-21
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
TICAGRELOR, BRILINTA, ASTRAZENECA
2025-11-09PED
2025-05-09M-283
2024-05-05PED
2023-11-28PED
2023-11-05I-848
2023-05-28I-851
Patent Expiration
Patent
Expires
Flag
FDA Information
Ticagrelor, Brilinta, Astrazeneca
103000652036-01-27U-2541, U-2542
84259342030-04-17DP
RE462762024-10-30DS, DPU-1935, U-1936, U-1937, U-1938, U-2838, U-2839, U-2988
ATC Codes
B: Blood and blood forming organ drugs
B01: Antithrombotic agents
B01A: Antithrombotic agents
B01AC: Platelet aggregation inhibitors excl. heparin
B01AC24: Ticagrelor
HCPCS
Code
Description
G9531
Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar
Clinical
Clinical Trials
372 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute coronary syndromeD054058EFO_00056722614491989
Coronary artery diseaseD003324I25.111215461281
Myocardial infarctionD009203EFO_0000612I21818531
St elevation myocardial infarctionD0000726572819231
Healthy volunteers/patients134219
Percutaneous coronary interventionD062645146616
Unstable anginaD000789EFO_1000985I20.0111012
Atrial fibrillationD001281EFO_0000275I48.014611
Cardiovascular diseasesD002318EFO_0000319I981125110
Inferior wall myocardial infarctionD056989EFO_1000983116210
Show 44 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ischemic strokeD000083242718
Sickle cell anemiaD000755EFO_0000697D572226
Transient ischemic attackD002546EFO_0003764G45.9155
Peripheral vascular diseasesD016491EFO_0003875I73.911
Bartter syndromeD001477Orphanet_112E26.8111
Drug-related side effects and adverse reactionsD064420T88.711
Intracranial arteriosclerosisD002537EFO_1000860I67.211
Cerebral infarctionD002544I6311
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Carotid stenosisD0168931113
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.922
PneumoniaD011014EFO_0003106J18112
Critical illnessD01663811
Abdominal aortic aneurysmD017544EFO_000421411
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD01059933
Renal insufficiencyD051437HP_0000083N19112
Therapeutic equivalencyD01381011
Biological availabilityD00168211
Acute lung injuryD055371EFO_000461011
Healthcare-associated pneumoniaD00007729911
GoutD006073EFO_0004274M1011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-eluting stentsD05485522
Coronary occlusionD054059I2111
Surgical blood lossD01606311
HemolysisD00646111
EndotoxemiaD01944611
HemorrhageD006470MP_0001914R5811
Balloon angioplastyD00080011
Dual anti-platelet therapyD00008090311
DyspneaD004417HP_0002094R06.011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTICAGRELOR
INNticagrelor
Description
Ticagrelor is a triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome. It has a role as a platelet aggregation inhibitor and a P2Y12 receptor antagonist. It is a member of triazolopyrimidines, an organofluorine compound, an aryl sulfide, a secondary amino compound and a hydroxyether.
Classification
Small molecule
Drug classplatelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Identifiers
PDB
CAS-ID274693-27-5
RxCUI1116632
ChEMBL IDCHEMBL398435
ChEBI ID68558
PubChem CID9871419
DrugBankDB08816
UNII IDGLH0314RVC (ChemIDplus, GSRS)
Target
Agency Approved
P2RY12
P2RY12
Organism
Homo sapiens
Gene name
P2RY12
Gene synonyms
HORK3
NCBI Gene ID
Protein name
P2Y purinoceptor 12
Protein synonyms
ADP-glucose receptor, ADPG-R, G-protein coupled receptor SP1999, Gi-coupled ADP receptor HORK3, P2T(AC), P2Y(AC), P2Y(ADP), P2Y(cyc), P2Y12 platelet ADP receptor, purinergic receptor P2RY12, purinergic receptor P2Y, G-protein coupled, 12, putative G-protein coupled receptor, SP1999
Uniprot ID
Mouse ortholog
P2ry12 (70839)
P2Y purinoceptor 12 (Q9CPV9)
Alternate
SLC29A1
SLC29A1
Organism
Homo sapiens
Gene name
SLC29A1
Gene synonyms
ENT1
NCBI Gene ID
Protein name
equilibrative nucleoside transporter 1
Protein synonyms
Equilibrative NBMPR-sensitive nucleoside transporter, equilibrative nitrobenzylmercaptopurine riboside (NBMPR)-sensitive nucleoside transporter, Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter, es nucleoside transporter, Nucleoside transporter, es-type, solute carrier family 29 (equilibrative nucleoside transporter), member 1, solute carrier family 29 (nucleoside transporters), member 1, Solute carrier family 29 member 1
Uniprot ID
Mouse ortholog
Slc29a1 (63959)
equilibrative nucleoside transporter 1 (Q9JIM1)
Variants
Clinical Variant
No data
Financial
Brilinta - AstraZeneca
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 9,812 documents
View more details
Safety
Black-box Warning
Black-box warning for: Brilinta, Ticagrelor
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
32,748 adverse events reported
View more details